LPA1 Modulation: Admilparant’s Role in the Evolution of IPF and PPF Therapies
Eric Cannon, PharmD, FAMCP, discusses how LPA1 receptor activation promotes fibrosis in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) through myofibroblast differentiation and ECM production. Admilparant shows promising antifibrotic activity in preclinical models but requires phase 3 efficacy data. As a novel targeted therapy, it may complement existing antifibrotics, particularly for progressive phenotypes with high LPA1 expression.
Video content above is prompted by the following:
- What evidence supports the role of LPA1 in modulating fibrotic processes, particularly in IPF and PPF?
- What has the data demonstrated with admilparant so far, and what future data is needed for this therapy?
- How do you envision admilparant fitting into treatment algorithms for patients with IPF and PPF?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024
October 18th 2024Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.
Read More
